• Immunofluorescence analysis of Rat-heart tissue. 1, PR monoclonal antibody (Z15) (red) was diluted at 1:200 (4°C, overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min).3, Picture B: DAPI (blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B
  • Immunohistochemical analysis of paraffin-embedded human breast caricnoma using PR monoclonal antibody.
  • Immunofluorescence analysis of Mouse-liver tissue. 1, PR monoclonal antibody (Z15) (red) was diluted at 1:200 (4°C, overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min).3, Picture B: DAPI (blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B
  • Immunofluorescence analysis of Human-appendix tissue. 1, PR monoclonal antibody (Z15) (red) was diluted at 1:200 (4°C, overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min).3, Picture B: DAPI (blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B
  • Immunohistochemical analysis of paraffin-embedded Mouse-testis tissue. 1, PR monoclonal antibody (Z15) was diluted at 1:200 (4°C, overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval (>98°C, 20min). 3, Secondary antibody was diluted at 1:200 (room tempeRature, 30min). Negative control was used by secondary antibody only.
  • Immunohistochemical analysis of paraffin-embedded Rat-testis tissue. 1, PR monoclonal antibody (Z15) was diluted at 1:200 (4°C, overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval (>98°C, 20min). 3, Secondary antibody was diluted at 1:200 (room tempeRature, 30min). Negative control was used by secondary antibody only.
  • Immunohistochemical analysis of paraffin-embedded Human-uterus tissue. 1, PR monoclonal antibody (Z15) was diluted at 1:200 (4°C, overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval (>98°C, 20min). 3, Secondary antibody was diluted at 1:200 (room tempeRature, 30min). Negative control was used by secondary antibody only.

Anti-PGR antibody [Z15] (STJ97365)

SKU:
STJ97365

Current Stock:
Host: Mouse
Applications: IHC/IF
Reactivity: Human/Mouse/Rat
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Mouse monoclonal antibody anti-Progesterone receptor is suitable for use in Immunohistochemistry and Immunofluorescence research applications.
Clonality: Monoclonal
Clone ID: Z15
Conjugation: Unconjugated
Isotype: IgG1
Formulation: Liquid in PBS pH7.4, 0.5% BSA, 0.02% Sodium Azide and 50% Glycerol.
Purification: The antibody was affinity-purified from mouse ascites by affinity-chromatography using epitope-specific immunogen.
Dilution Range: IHC 1:200
IF 1:100-200
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: PGR
Gene ID: 5241
Uniprot ID: PRGR_HUMAN
Specificity: The antibody detects endogenous PR protein.
Immunogen: Synthetic Peptide of PR
Post Translational Modifications Phosphorylated on multiple serine sites. Several of these sites are hormone-dependent. Phosphorylation on Ser-294 occurs preferentially on isoform B, is highly hormone-dependent and modulates ubiquitination and sumoylation on Lys-388. Phosphorylation on Ser-102 and Ser-345 also requires induction by hormone. Basal phosphorylation on Ser-81, Ser-162, Ser-190 and Ser-400 is increased in response to progesterone and can be phosphorylated in vitro by the CDK2-A1 complex. Increased levels of phosphorylation on Ser-400 also in the presence of EGF, heregulin, IGF, PMA and FBS. Phosphorylation at this site by CDK2 is ligand-independent, and increases nuclear translocation and transcriptional activity. Phosphorylation at Ser-162 and Ser-294, but not at Ser-190, is impaired during the G(2)/M phase of the cell cycle. Phosphorylation on Ser-345 by ERK1/2 MAPK is required for interaction with SP1. Sumoylation is hormone-dependent and represses transcriptional activity. Sumoylation on all three sites is enhanced by PIAS3. Desumoylated by SENP1. Sumoylation on Lys-388, the main site of sumoylation, is repressed by ubiquitination on the same site, and modulated by phosphorylation at Ser-294. Ubiquitination is hormone-dependent and represses sumoylation on the same site. Promoted by MAPK-mediated phosphorylation on Ser-294. Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation is required for plasma membrane targeting and for rapid intracellular signaling via ERK and AKT kinases and cAMP generation.
Function The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Depending on the isoform, progesterone receptor functions as transcriptional activator or repressor. Isoform A: Ligand-dependent transdominant repressor of steroid hormone receptor transcriptional activity including repression of its isoform B, MR and ER. Transrepressional activity may involve recruitment of corepressor NCOR2. Isoform B: Transcriptional activator of several progesteron-dependent promoters in a variety of cell types. Involved in activation of SRC-dependent MAPK signaling on hormone stimulation. Isoform 4: Increases mitochondrial membrane potential and cellular respiration upon stimulation by progesterone.
Protein Name Progesterone Receptor
Pr
Nuclear Receptor Subfamily 3 Group C Member 3
Database Links Reactome: R-HSA-1251985
Reactome: R-HSA-3371497
Reactome: R-HSA-383280
Reactome: R-HSA-4090294
Reactome: R-HSA-9018519
Cellular Localisation Nucleus
Cytoplasm
Nucleoplasmic Shuttling Is Both Hormone- And Cell Cycle-Dependent
On Hormone Stimulation
Retained In The Cytoplasm In The G(1) And G(2)/M Phases
Isoform A: Nucleus
Mainly Nuclear
Isoform 4: Mitochondrion Outer Membrane
Alternative Antibody Names Anti-Progesterone Receptor antibody
Anti-Pr antibody
Anti-Nuclear Receptor Subfamily 3 Group C Member 3 antibody
Anti-PGR antibody
Anti-NR3C3 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance